Cargando...
Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer
BACKGROUND: Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers. This study reviewed the HPD in patients with AGC treated with nivolumab or irinotec...
Guardado en:
| Publicado en: | ESMO Open |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMJ Publishing Group
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6555603/ https://ncbi.nlm.nih.gov/pubmed/31231567 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000488 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|